Skip to main content
. 2023 Jan 9;27:8. doi: 10.1186/s13054-022-04292-7

Table 2.

Primary and secondary outcomes

Placebo (n = 118) Valproic acid (n = 126) Risk difference* (95% CI) Relative risk* (95% CI) P
Primary outcome
Intention to treat 72/118 (61%) 77/126 (61%)  + 2.5% (− 6.3 to 11.2) 1.04 (0.90 to 1.20) 0.58
Worst-case scenario 73/118 (62%) 77/126 (61%)  + 1.8% (− 7.5 to 11.1) 1.03 (0.88 to 1.20) 0.70
Available data 72/117 (62%) 77/125 (62%)  + 2.6% (− 7.3 to 12.5) 1.04 (0.89 to 1.23) 0.60
Secondary outcomes
Refractory status epilepticus 6/118 (5%) 5/126 (4%) − 0.9% (− 5.6 to 3.8) 0.82 (0.32 to 2.08) 0.68
Super-refractory status epilepticus 4/118 (3%) 3/126 (2%) − 1.0% (− 5.7 to 3.7) 0.71 (0.17 to 2.96) 0.64
Recurrence of seizure during ICU stay‡ 14/118 (12%) 7/125 (6%) − 6.1% (− 15.2 to 3.0) 0.48 (0.23 to 1.00) 0.049
Time to awakening (hours) 18 (9–72) [n = 117] 24 (12–72)
[n = 121] 0.84 (0.64 to 1.10)§ 0.21
Length of ICU stay (days) 4 (3–7) 5 (3–8) 0.91 (0.70 to 1.18)§ 0.46
Length of hospital stay (days) 11 (7–23) 12 (7–24) 0.97 (0.75 to 1.27)§ 0.84
Highest SOFA score¶ 4 (2–7) [n = 76] 4 (2–6) [n = 74]  + 0.2 (− 0.9 to 1.4) ‖ 0.68
Death in ICU 2/118 (2%) 4/126 (3%)  + 1.6% (− 2.5 to 5.8) 1.99 (0.48 to 8.27) 0.35
Death in hospital 2/118 (2%) 7/126 (6%)  + 4.0% (− 0.7 to 8.7) 2.94 (0.61 to 14.3)§ 0.18
Death from randomisation to day 90 3/118 (3%) 8/126 (6%)  + 4.7% (− 1.9 to 11.3) 2.32 (0.61 to 8.84)** 0.22
MMSE score at day 90 26 (21–29) [n = 21] 26 (23–28) [n = 18] − 0.2 (− 4.7 to 4.2) ‖ 0.92
FAB score at day 90 14 (12–17) [n = 26] 15 (12–18) [n = 23]  + 0.2 (− 2.1 to 2.5) ‖ 0.16
Glasgow Outcome Score at day 90 5 (4–5) [n = 44] 4 (3–5) [n = 55] 0.71 (0.33 to 1.58)††

Data are n/N (%) or median (first–third quartile) unless otherwise stated

* Adjusted for randomisation strata (age ≤ 65 or > 65 years, and presence or absence of acute brain injury), and centre

Defined by the proportion of patients discharged alive from hospital to their home or to a long-term care facility on day 15

Defined by the recurrence of seizure or status epilepticus in patients for whom GCSE has been controlled

§ Adjusted sub-distribution hazard ratio

Worst score day 2 to day 15

‖ Adjusted mean difference

** Adjusted hazard ratio

†† Adjusted odds ratio estimated in a Bayesian proportional odds model; no P-value is computed

CI Confidence interval; FAB Frontal Assessment Battery [38]; ICU Intensive care unit; MMSE Mini-Mental State Examination [39]; SOFA Sepsis-related Organ Failure Assessment